Unpublished conference/Abstract (Scientific congresses and symposiums)
Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial
Kelly, K.; Patel, M.; Infante, J.R. et al.
2016American Association for Cancer Research Annual Meeting
 

Files


Full Text
Safety of Avelumab (MSB0010718C), an anti-PD-L1 antibody ... abstract.pdf
Publisher postprint (602.06 kB)
Request a copy
Annexes
Safety of Avelumab (MSB0010718C), an anti-PD-L1 antibody ... dias.pdf
Publisher postprint (343.7 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
oncology
Disciplines :
Oncology
Author, co-author :
Kelly, K.
Patel, M.
Infante, J.R.
Iannotti, N.
Nikolinakos, P.
Leach, J.
Wang, D.
Chandler, J.
JERUSALEM, Guy  ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'oncologie médicale
Gurtler, J.
Arkenau, H-T.
Bajars, M.
von Heydebreck, A.
Speit, I.
Heery, Ch.
Gulley, J.L.
More authors (6 more) Less
Language :
English
Title :
Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial
Publication date :
April 2016
Event name :
American Association for Cancer Research Annual Meeting
Event place :
New Orleans, United States
Event date :
April 16-20, 2016
Audience :
International
References of the abstract :
CT132
Available on ORBi :
since 07 July 2016

Statistics


Number of views
52 (0 by ULiège)
Number of downloads
0 (0 by ULiège)

Bibliography


Similar publications



Contact ORBi